Although NSCLC with EGFR-activating mutations exhibits sensitivity to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, most patients treated with EGFR-TKIs develop resistance within 10–14 months3. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.